Piramal Pharma targets mid-teen FY27 growth, favours organic expansion

Piramal Pharma is prioritising greenfield and organic investment over acquisitions after April–June revenue rose 17% year on year to Rs 2,270 crore. EBITDA increased 72% to Rs 285 crore, lifting margin by 400 basis points to 12.5%.

— Source publishedThu, 30 Jul, 2026, 13:29 IST·First seen Thu, 30 Jul, 2026, 13:38 IST·Source Business Standard · Companies

What happened

Piramal Pharma targets mid-teen FY27 revenue growth and faster EBITDA expansion, prioritising greenfield and organic investment over acquisitions. Its consumer

Key facts

  • FY27 revenue growth guidance: mid-teens
  • April-June consolidated revenue: Rs 2,270 crore, up 17% YoY
  • April-June EBITDA: Rs 285 crore, up 72% YoY
  • EBITDA margin: 12.5%, up 400 basis points from 8.5%
  • Net loss: Rs 69 crore versus Rs 102 crore loss a year earlier
  • CDMO revenue: Rs 1,187 crore, up 19% YoY

Why this matters

By explicitly favouring organic and greenfield expansion over acquisitions, Piramal Pharma indicates that near-term capital allocation will focus on internal capabilities rather than dealmaking.

What to watch

  • Quarterly revenue growth versus the mid-teen FY27 target.
  • Whether EBITDA margin remains near or above the 12.5% June-quarter level after capex and mix changes.
  • Capex announcements, commissioning schedules, and utilization rates at new or expanded facilities.
  • Large customer wins, contract renewals, and conversion of development-stage projects to commercial supply.
  • Order-book visibility and management commentary on global CDMO demand.
  • Free cash flow, net debt trends, and working-capital intensity during the organic investment cycle.
  • Evidence of pricing pressure, regulatory observations, customer concentration changes, or delays in product approvals.
  • Prioritize brownfield debottlenecking and selected greenfield projects in higher-utilization CDMO and differentiated product areas.
  • Use the improved EBITDA base to fund capex internally while maintaining balance-sheet discipline rather than pursuing large acquisitions.
  • Focus commercial resources on multi-year contracts, late-stage development programs, and cross-selling across pharma services businesses.
  • Seek to convert margin improvement into durable gains through procurement savings, plant productivity, and a higher mix of value-added offerings.
  • Provide investors with capacity commissioning, utilization, order-book, and cash-flow milestones to validate the FY27 target.